Education
About Us
Working with TipRanks
Follow Us
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
Earnings Data
Report Date
May 06, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.19Last Year’s EPS
-0.28Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented multiple high-impact near-term catalysts (April MRD readout for ALPHA-3 and June proof-of-concept data for ALLO-329), a differentiated autoimmune approach with potential low/no lymphodepletion, and an extended cash runway into 2028 to support prioritized programs. However, the company faces meaningful financial losses, dependence on surrogate MRD endpoints with incomplete linkage to clinical outcomes, competitive headwinds from frontline bispecifics, and uncertainty around safety and small-sample interim analyses. On balance, the call emphasized execution readiness and funding to reach key inflection points while acknowledging important clinical and market risks.Company Guidance
Upcoming Clinical Catalysts and Timelines
ALPHA-3 (SemiCell) interim futility MRD analysis planned for April 2026 on 24 patients (12 per arm); ALLO-329 proof-of-concept translational and early clinical signals expected in June 2026; additional clinical updates anticipated later in 2026.
Ambitious MRD Efficacy Target for ALPHA-3
Company anchored expectations around a 25% to 30% absolute delta in MRD clearance between SemiCell-treated and observation arms—a threshold management calls potentially practice-changing for first-line large B-cell lymphoma.
Broad Clinical Footprint for SemiCell
SemiCell is active in over 60 clinical sites across the U.S. and Canada with site start-up activities underway in Australia and South Korea, emphasizing community integration and outpatient delivery as a strategic advantage of the off-the-shelf model.
ALLO-329 Differentiated Autoimmune Program
ALLO-329 is a dual CD19/CD70 allogeneic CAR T designed with Dagger technology to enable in vivo expansion at low cell doses; study starts at 20 million CAR-T cells (significantly lower than competitors—autologous programs 5x–10x higher, other allogeneic programs up to ~50x higher); cohorts include cyclophosphamide-only and no lymphodepletion to test low/no lymphodepletion feasibility.
Extended Cash Runway into 2028
As of 12/31/2025 cash, cash equivalents, and investments were $258.3 million; company received an additional $23.7 million from escrow in February and raised $20.7 million YTD via ATM, extending runway into 2028 to support completion of ALPHA-3 enrollment.
Focused Prioritization and Capital Allocation
Management has prioritized resources behind ALPHA-3 and RESOLUTION (ALLO-329), highlighting discipline in advancing high-impact programs and explicitly linking cash runway to execution of these pivotal studies.
Clear Financial Guidance for 2026
Guidance provided: operating cash expense ~ $150 million for 2026; GAAP operating expenses ~ $210 million including estimated ~$35 million of non-cash stock-based compensation—giving investors visibility into near-term burn and planning assumptions.
ALLO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ALLO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 12, 2026 | $2.47 | $2.40 | -2.83% |
Nov 06, 2025 | $1.05 | $1.18 | +12.38% |
Aug 13, 2025 | $1.04 | $1.07 | +2.88% |
May 13, 2025 | $1.13 | $0.95 | -15.93% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Allogene Therapeutics Inc (ALLO) report earnings?
Allogene Therapeutics Inc (ALLO) is schdueled to report earning on May 06, 2026, Before Open (Confirmed).
What is Allogene Therapeutics Inc (ALLO) earnings time?
Allogene Therapeutics Inc (ALLO) earnings time is at May 06, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ALLO EPS forecast?
ALLO EPS forecast for the fiscal quarter 2026 (Q1) is -0.19.